In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs.
We have previously demonstrated successful in vivo selection, chemoprotection, and modulation of donor chimerism in dogs that received myeloablative allogeneic stem cell transplantation with cells expressing the P140K mutant of the DNA repair enzyme methylguanine methyltransferase (MGMTP140K). Here, we wished to investigate whether in vivo selection, chemoprotection, and modulation of donor chimerism could also be achieved after nonmyeloablative transplantation, which could allow for less toxic transplantation regimens for patients with malignant and genetic diseases. Three dogs received a nonmyeloablative conditioning regimen and infusion of allogeneic stem cells transduced with MGMTP140K. All three dogs had stable gene marking and donor chimerism before receiving a course of O(6) -benzylguanine (O(6) BG)/1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) between days 210 and 589 after transplantation. One to four doses led to a marked increase in gene marking in all dogs. Furthermore, the transduced cells conferred chemoprotection and prevented severe neutropenia. Our results suggest that drug resistance gene therapy is feasible and safe in the nonmyeloablative transplantation setting.
Gerull
Sabine
S
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Beard
Brian C
BC
Peterson
Laura J
LJ
Neff
Tobias
T
Kiem
Hans-Peter
HP
D000818:Animals; D001483:Base Sequence; D002330:Carmustine / Q000627:therapeutic use; D017931:DNA Primers / Q000235:genetics; D004285:Dogs; D004351:Drug Resistance / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006082:Graft Enhancement, Immunologic; D016086:Lentivirus / Q000235:genetics; D033581:Stem Cell Transplantation; D018183:Transplantation Chimera; D014184:Transplantation, Homologous
D017931:DNA Primers; D002330:Carmustine